Abstract:Background: Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM or CAD. However, studies assessing the predictive capacity of novel metabolomics biomarkers in coexistent CAD and DM are scarce. Methods: This post-hoc analysis of the CorLipid trial (NCT04580173) included 316 patients with CAD and comorbid DM who underwent emergency or elective coronary angiography due to acute or chronic coronary syndrome. Cox regression analyses were performed to identify metabolomic predictors of the primary outcome, which was defined as the composite of major adverse cardiovascular or cerebrovascular events (MACCE: cardiovascular death, myocardial infarction, stroke, major bleeding), repeat unplanned revascularizations and cardiovascular hospitalizations. Linear regression analyses were also performed to detect significant predictors of CAD complexity, as assessed by the SYNTAX score. Results: After a median 2-year follow up period (IQR = 0.7 years), the primary outcome occurred in 69 (21.8%) of patients. Acylcarnitine ratio C4/C18:2, apolipoprotein (apo) B, history of heart failure (HF), age > 65 years and presence of acute coronary syndrome were independent predictors of the primary outcome in diabetic patients with CAD (aHR = 1.89 [1.09, 3.29]; 1.02 [1.01, 1.04]; 1.28 [1.01, 1.41]; 1.04 [1.01, 1.05]; and 1.12 [1.05-1.21], respectively). Higher levels of ceramide ratio C24:1/C24:0, acylcarnitine ratio C4/C18:2, age > 65 and peripheral artery disease were independent predictors of higher CAD complexity (adjusted β = 7.36 [5.74, 20.47]; 3.02 [0.09 to 6.06]; 3.02 [0.09, 6.06], respectively), while higher levels of apoA1 were independent predictors of lower complexity (adjusted β= - 0.65 [- 1.31, - 0.02]). Conclusions: In patients with comorbid DM and CAD, novel metabolomic biomarkers and metabolomics-based prediction models could be recruited to predict clinical outcomes and assess the complexity of CAD, thereby enabling the integration of personalized medicine into routine clinical practice. These associations should be interpreted taking into account the observational nature of this study, and thus, larger trials are needed to confirm its results and validate them in different and larger diabetic populations.

An integrative multiomic network model links lipid metabolism to glucose regulation in coronary artery disease

A mechanistic framework for cardiometabolic and coronary artery diseases

Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease

Integrative genomic analysis identified common regulatory networks underlying the correlation between coronary artery disease and plasma lipid levels

Conditional GWAS Revealing Genetic Impacts of Lifestyle Behaviors on Low-Density Lipoprotein (LDL)

Alterations of a Cellular Cholesterol Metabolism Network Are a Molecular Feature of Obesity-Related Type 2 Diabetes and Cardiovascular Disease

Cardiometabolic Risk Loci Share Downstream Cis- and Trans-Gene Regulation Across Tissues and Diseases

Comprehensive Metabolomics Identified the Prominent Role of Glycerophospholipid Metabolism in Coronary Artery Disease Progression

LXR signaling pathways link cholesterol metabolism with risk for prediabetes and diabetes

Gene networks and pathways for plasma lipid traits via multitissue multiomics systems analysis

Integrated systems approach identifies pathways from the genome to triglycerides through a metabolomic causal network

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

Type 2 Diabetes Modifies the Association of CAD Genomic Risk Variants With Subclinical Atherosclerosis

Integrative analysis of liver-specific non-coding regulatory SNPs associated with the risk of coronary artery disease

Decoding cardiovascular risks: analyzing type 2 diabetes mellitus and ASCVD gene expression

Lipid Metabolic Networks, Mediterranean Diet and Cardiovascular Disease in the PREDIMED Trial.

Functional Characterization of Lipid Regulatory Effects of Three Genes Using Knockout Mouse Models

Integrated multi-omic high-throughput strategies across-species identified potential key diagnostic, prognostic, and therapeutic targets for atherosclerosis under high glucose conditions

Metabolic reaction fluxes as amplifiers and buffers of risk alleles for coronary artery disease

Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomization